Krishna Jayaraman, MD
Urology · Mechanicsville, MDNPI 1346246881
Payments from drug & device makers
Across 261 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$850
- Bayer$687
- Endo Pharmaceuticals Inc.$409
- Astellas Pharma US Inc$381
- Pfizer$380
- AbbVie$332
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,28398%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 40 | $850 |
| Bayer | 26 | $687 |
| Endo Pharmaceuticals Inc. | 22 | $409 |
| Astellas Pharma US Inc | 17 | $381 |
| Pfizer | 26 | $380 |
| AbbVie(2 entities) | 17 | $332 |
| Endo USA, Inc. | 10 | $207 |
| Sumitomo Pharma America, Inc. | 8 | $185 |
| Acerus Pharmaceuticals Corporation | 9 | $178 |
| Antares Pharma, Inc. | 9 | $177 |
| Laborie Medical Technologies Corp. | 3 | $155 |
| Coloplast | 8 | $115 |
| Tolmar, Inc. | 4 | $107 |
| Tolmar Pharmaceuticals, Inc. | 6 | $95 |
| 180 Medical, Inc. | 4 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Caldera Medical, Inc | 1 | $88 |
| Myovant Sciences Inc. | 4 | $82 |
| Merck | 4 | $75 |
| Urovant Sciences Inc | 5 | $74 |
| Dentsply IH AB | 3 | $56 |
| Duchesnay USA Incorporated | 2 | $48 |
| Boston Scientific | 3 | $46 |
| Olympus America Inc. | 2 | $46 |
| Novo Nordisk | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Abbott | 2 | $38 |
| Foundation Medicine, Inc. | 2 | $36 |
| Integra Lifesciences Corporation | 1 | $33 |
| Axonics, Inc. | 1 | $31 |
| Accord Healthcare, Inc. | 1 | $28 |
| Halozyme Inc | 1 | $25 |
| Immunitybio, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 3 | $19 |
| Neotract Inc. | 1 | $18 |
| Convatec Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Dentsply IH Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Blue Earth Diagnostics | 1 | $13 |
How this compares
$5,366 in reported general payments places this provider in the 50th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 27 | $516,894 |
| XtandiEnzalutamide | 13 | $186,621 |
| MyrbetriqMirabegron | 87 | $67,767 |
| GemtesaVibegron | 85 | $67,335 |
| OrgovyxRelugolix | 11 | $30,688 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 38 | $6,886 |
| Tamsulosin Hcl | 343 | $5,860 |
| Dutasteride | 142 | $4,931 |
| Potassium Citrate ErPotassium Citrate | 22 | $4,217 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 32 | $3,727 |
| Finasteride | 139 | $2,377 |
| Testosterone Cypionate | 27 | $1,876 |
| Tadalafil | 15 | $1,519 |
| Oxybutynin Chloride ErOxybutynin Chloride | 73 | $1,418 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $850 | $516,89427 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $381 | $254,388100 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $185 | $98,02296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 274 urology providers in Maryland.
Other urology in Mechanicsville
- Matthew AllawayCumberland$20.6M
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
- Benjamin LowentrittBaltimore$994K
- Rian DicksteinHanover$750K
- Laura GiustoOwings Mills$628K
- Kenneth LangerBaltimore$610K
- Arvin GeorgeBaltimore$518K
- Julio DavalosGlen Burnie$503K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.